Drug Policy Review 2022-2023

The Inflation Reduction Act’s drug-pricing reforms headlined a flurry of drug-related policy activity over the last year. The action was not limited to Congress, as the Biden administration took some federal actions to lower drug prices but held off on others; federal courts decided cases centered on financial flows in the drug value chain; and states adopted interventions geared at lowering costs for patients.

In this paper, John Barkett, Mara Kash, and Jose Gonzalez traverse the landscape of drug-pricing reform efforts in 2022-2023 and highlight what to watch in the coming year.